|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu C, Qin T, Huang Y, Li Y, Chen G and
Sun C: Drug screening model meets cancer organoid technology.
Transl Oncol. 13:1008402020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Magré L, Verstegen MMA, Buschow S, van der
Laan LJW, Peppelenbosch M and Desai J: Emerging organoid-immune
co-culture models for cancer research: From oncoimmunology to
personalized immunotherapies. J Immunother Cancer. 11:e0062902023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drapkin BJ, George J, Christensen CL,
Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J,
Igo P, et al: Genomic and functional fidelity of small cell lung
cancer patient-derived xenografts. Cancer Discov. 8:600–615. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Izumchenko E, Paz K, Ciznadija D, Sloma I,
Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris
W, et al: Patient-derived xenografts effectively capture responses
to oncology therapy in a heterogeneous cohort of patients with
solid tumors. Ann Oncol. 28:2595–2605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saito R, Kobayashi T, Kashima S, Matsumoto
K and Ogawa O: Faithful preclinical mouse models for better
translation to bedside in the field of immuno-oncology. Int J Clin
Oncol. 25:831–841. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ben-David U, Ha G, Tseng YY, Greenwald NF,
Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R and Golub
TR: Patient-derived xenografts undergo mouse-specific tumor
evolution. Nat Genet. 49:1567–1575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao
M, Hu H, Xu M, Guo X and Liu Y: Human organoids in basic research
and clinical applications. Signal Transduct Target Ther. 7:1682022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen P, Zhang X, Ding R, Yang L, Lyu X,
Zeng J, Lei JH, Wang L, Bi J, Shao N, et al: Patient-derived
organoids can guide personalized-therapies for patients with
advanced breast cancer. Adv Sci (Weinh). 8:e21011762021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu KS, Adileh M, Martin ML, Makarov V,
Chen J, Wu C, Bodo S, Klingler S, Sauvé CG, Szeglin BC, et al:
Colorectal cancer develops inherent radiosensitivity that can be
predicted using patient-derived organoids. Cancer Res.
82:2298–2312. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seppälä TT, Zimmerman JW, Suri R, Zlomke
H, Ivey GD, Szabolcs A, Shubert CR, Cameron JL, Burns WR, Lafaro
KJ, et al: Precision medicine in pancreatic cancer: Patient-derived
organoid pharmacotyping is a predictive biomarker of clinical
treatment response. Clin Cancer Res. 28:3296–3307. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang HM, Zhang CY, Peng KC, Chen ZX, Su
JW, Li YF, Li WF, Gao QY, Zhang SL, Chen YQ, et al: Using
patient-derived organoids to predict locally advanced or metastatic
lung cancer tumor response: A real-world study. Cell Rep Med.
4:1009112023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Drost J and Clevers H: Organoids in cancer
research. Nat Rev Cancer. 18:407–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wilson HV: A new method by which sponges
may be artificially reared. Science. 25:912–915. 1907. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lindberg K, Brown ME, Chaves HV, Kenyon KR
and Rheinwald JG: In vitro propagation of human ocular surface
epithelial cells for transplantation. Invest Ophthalmol Vis Sci.
34:2672–2679. 1993.PubMed/NCBI
|
|
16
|
Pellegrini G, Traverso CE, Franzi AT,
Zingirian M, Cancedda R and De Luca M: Long-term restoration of
damaged corneal surfaces with autologous cultivated corneal
epithelium. Lancet. 349:990–993. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim JY, Nam Y, Rim YA and Ju JH: Review of
the current trends in clinical trials involving induced pluripotent
stem cells. Stem Cell Rev Rep. 18:142–154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng H, Liu C, Cai X, Lu Y, Xu Y and Yu
X: iPSCs derived from malignant tumor cells: Potential application
for cancer research. Curr Stem Cell Res Ther. 11:444–450. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Orqueda AJ, Giménez CA and Pereyra-Bonnet
F: iPSCs: A minireview from bench to bed, including organoids and
the crispr system. Stem Cells Int. 2016:59347822016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dimos JT, Rodolfa KT, Niakan KK,
Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R,
Goland R, et al: Induced pluripotent stem cells generated from
patients with ALS can be differentiated into motor neurons.
Science. 321:1218–1221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato T, Vries RG, Snippert HJ, van de
Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters
PJ and Clevers H: Single Lgr5 stem cells build crypt-villus
structures in vitro without a mesenchymal niche. Nature.
459:262–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuratnik A and Giardina C: Intestinal
organoids as tissue surrogates for toxicological and
pharmacological studies. Biochem Pharmacol. 85:1721–1726. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spence JR, Mayhew CN, Rankin SA, Kuhar MF,
Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn
AM, et al: Directed differentiation of human pluripotent stem cells
into intestinal tissue in vitro. Nature. 470:105–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eiraku M, Takata N, Ishibashi H, Kawada M,
Sakakura E, Okuda S, Sekiguchi K, Adachi T and Sasai Y:
Self-organizing optic-cup morphogenesis in three-dimensional
culture. Nature. 472:51–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD and Clevers H: Long-term expansion of epithelial
organoids from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu M, Bardia A, Aceto N, Bersani F, Madden
MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al:
Cancer therapy. Ex vivo culture of circulating breast tumor cells
for individualized testing of drug susceptibility. Science.
345:216–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boj SF, Hwang CI, Baker LA, Chio II, Engle
DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, et al:
Organoid models of human and mouse ductal pancreatic cancer. Cell.
160:324–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bartfeld S, Bayram T, van de Wetering M,
Huch M, Begthel H, Kujala P, Vries R, Peters PJ and Clevers H: In
vitro expansion of human gastric epithelial stem cells and their
responses to bacterial infection. Gastroenterology. 148:126–136.e6.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hubert CG, Rivera M, Spangler LC, Wu Q,
Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE and Rich JN: A
three-dimensional organoid culture system derived from human
glioblastomas recapitulates the hypoxic gradients and cancer stem
cell heterogeneity of tumors found in vivo. Cancer Res.
76:2465–2477. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Broutier L, Mastrogiovanni G, Verstegen
MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R,
Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived
organoid cultures for disease modeling and drug screening. Nat Med.
23:1424–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Girda E, Huang EC, Leiserowitz GS and
Smith LH: The use of endometrial cancer patient-derived organoid
culture for drug sensitivity testing is feasible. Int J Gynecol
Cancer. 27:1701–1707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pauli C, Hopkins BD, Prandi D, Shaw R,
Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, et al:
Personalized in vitro and in vivo cancer models to guide precision
medicine. Cancer Discov. 7:462–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kijima T, Nakagawa H, Shimonosono M,
Chandramouleeswaran PM, Hara T, Sahu V, Kasagi Y, Kikuchi O, Tanaka
K, Giroux V, et al: Three-Dimensional organoids reveal therapy
resistance of esophageal and oropharyngeal squamous cell carcinoma
cells. Cell Mol Gastroenterol Hepatol. 7:73–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka N, Osman AA, Takahashi Y, Lindemann
A, Patel AA, Zhao M, Takahashi H and Myers JN: Head and neck cancer
organoids established by modification of the CTOS method can be
used to predict in vivo drug sensitivity. Oral Oncol. 87:49–57.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kopper O, de Witte CJ, Lõhmussaar K,
Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost
N, Begthel H, et al: An organoid platform for ovarian cancer
captures intra- and interpatient heterogeneity. Nat Med.
25:838–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ,
Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, et al: Patient-derived
lung cancer organoids as in vitro cancer models for therapeutic
screening. Nat Commun. 10:39912019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grassi L, Alfonsi R, Francescangeli F,
Signore M, De Angelis ML, Addario A, Costantini M, Flex E, Ciolfi
A, Pizzi S, et al: Organoids as a new model for improving
regenerative medicine and cancer personalized therapy in renal
diseases. Cell Death Dis. 10:2012019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen D, Tan Y, Li Z, Li W, Yu L, Chen W,
Liu Y, Liu L, Guo L, Huang W and Zhao Y: Organoid cultures derived
from patients with papillary thyroid cancer. J Clin Endocrinol
Metab. 106:1410–1426. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wörsdörfer P, Takashi I, Asahina I, Sumita
Y and Ergün S: Do not keep it simple: Recent advances in the
generation of complex organoids. J Neural Transm (Vienna).
127:1569–1577. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Demyan L, Habowski AN, Plenker D, King DA,
Standring OJ, Tsang C, St Surin L, Rishi A, Crawford JM, Boyd J, et
al: Pancreatic cancer patient-derived organoids can predict
response to neoadjuvant chemotherapy. Ann Surg. 276:450–462. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Beato F, Reverón D, Dezsi KB, Ortiz A,
Johnson JO, Chen DT, Ali K, Yoder SJ, Jeong D, Malafa M, et al:
Establishing a living biobank of patient-derived organoids of
intraductal papillary mucinous neoplasms of the pancreas. Lab
Invest. 101:204–217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma C, Peng Y, Li H and Chen W:
Organ-on-a-Chip: A new paradigm for drug development. Trends
Pharmacol Sci. 42:119–133. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kutluk H, Bastounis EE and Constantinou I:
Integration of extracellular matrices into organ-on-chip systems.
Adv Healthc Mater. 12:e22032562023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Demers CJ, Soundararajan P, Chennampally
P, Cox GA, Briscoe J, Collins SD and Smith RL: Development-on-chip:
In vitro neural tube patterning with a microfluidic device.
Development. 143:1884–1892. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Wang L, Zhu Y and Qin J: Human
brain organoid-on-a-chip to model prenatal nicotine exposure. Lab
Chip. 18:851–860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shirure VS, Bi Y, Curtis MB, Lezia A,
Goedegebuure MM, Goedegebuure SP, Aft R, Fields RC and George SC:
Tumor-on-a-chip platform to investigate progression and drug
sensitivity in cell lines and patient-derived organoids. Lab Chip.
18:3687–3702. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Garreta E, Kamm RD, de Sousa Lopes SM,
Lancaster MA, Weiss R, Trepat X, Hyun I and Montserrat N:
Rethinking organoid technology through bioengineering. Nat Mater.
20:145–155. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jin Y, Kim J, Lee JS, Min S, Kim S, Ahn
DH, Kim YG and Cho SW: Vascularized liver organoids generated using
induced hepatic tissue and dynamic liver-specific microenvironment
as a drug testing platform. Adv Funct Mater. 28:18019542018.
View Article : Google Scholar
|
|
50
|
Miller CP, Tsuchida C, Zheng Y, Himmelfarb
J and Akilesh S: A 3D human renal cell carcinoma-on-a-chip for the
study of tumor angiogenesis. Neoplasia. 20:610–620. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Haque MR, Wessel CR, Leary DD, Wang C,
Bhushan A and Bishehsari F: Patient-derived pancreatic
cancer-on-a-chip recapitulates the tumor microenvironment.
Microsyst Nanoeng. 8:362022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Picollet-D'hahan N, Zuchowska A, Lemeunier
I and Le Gac S: Multiorgan-on-a-Chip: A systemic approach to model
and decipher inter-organ communication. Trends Biotechnol.
39:788–810. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mandrycky C, Wang Z, Kim K and Kim DH: 3D
bioprinting for engineering complex tissues. Biotechnol Adv.
34:422–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Datta P, Barui A, Wu Y, Ozbolat V, Moncal
KK and Ozbolat IT: Essential steps in bioprinting: From pre- to
post-bioprinting. Biotechnol Adv. 36:1481–1504. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang X, Luo Y, Ma Y, Wang P and Yao R:
Converging bioprinting and organoids to better recapitulate the
tumor microenvironment. Trends Biotechnol. 42:648–663. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ding S, Feng L, Wu J, Zhu F, Tan Z and Yao
R: Bioprinting of stem cells: Interplay of bioprinting process,
bioinks, and stem cell properties. ACS Biomater Sci Eng.
4:3108–3124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gaspar VM, Lavrador P, Borges J, Oliveira
MB and Mano JF: Advanced bottom-up engineering of living
architectures. Adv Mater. 32:e19039752020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yoon WH, Lee HR, Kim S, Kim E, Ku JH, Shin
K and Jung S: Use of inkjet-printed single cells to quantify
intratumoral heterogeneity. Biofabrication. 12:0350302020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mollica PA, Booth-Creech EN, Reid JA,
Zamponi M, Sullivan SM, Palmer XL, Sachs PC and Bruno RD: 3D
bioprinted mammary organoids and tumoroids in human mammary derived
ECM hydrogels. Acta Biomater. 95:201–213. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Reid JA, Palmer XL, Mollica PA, Northam N,
Sachs PC and Bruno RD: A 3D bioprinter platform for mechanistic
analysis of tumoroids and chimeric mammary organoids. Sci Rep.
9:74662019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Maloney E, Clark C, Sivakumar H, Yoo K,
Aleman J, Rajan SAP, Forsythe S, Mazzocchi A, Laxton AW, Tatter SB,
et al: Immersion bioprinting of tumor organoids in multi-well
plates for increasing chemotherapy screening throughput.
Micromachines (Basel). 11:2082020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mao S, He J, Zhao Y, Liu T, Xie F, Yang H,
Mao Y, Pang Y and Sun W: Bioprinting of patient-derived in vitro
intrahepatic cholangiocarcinoma tumor model: Establishment,
evaluation and anti-cancer drug testing. Biofabrication.
12:0450142020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bernal PN, Bouwmeester M, Madrid-Wolff J,
Falandt M, Florczak S, Rodriguez NG, Li Y, Größbacher G, Samsom RA,
van Wolferen M, et al: Volumetric bioprinting of organoids and
optically tuned hydrogels to build liver-like metabolic
biofactories. Adv Mater. 34:e21100542022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kleinman HK and Martin GR: Matrigel:
Basement membrane matrix with biological activity. Semin Cancer
Biol. 15:378–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Talbot NC and Caperna TJ: Proteome array
identification of bioactive soluble proteins/peptides in Matrigel:
Relevance to stem cell responses. Cytotechnology. 67:873–883. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Aisenbrey EA and Murphy WL: Synthetic
alternatives to Matrigel. Nat Rev Mater. 5:539–551. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ng S, Tan WJ, Pek MMX, Tan MH and Kurisawa
M: Mechanically and chemically defined hydrogel matrices for
patient-derived colorectal tumor organoid culture. Biomaterials.
219:1194002019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Below CR, Kelly J, Brown A, Humphries JD,
Hutton C, Xu J, Lee BY, Cintas C, Zhang X, Hernandez-Gordillo V, et
al: A microenvironment-inspired synthetic three-dimensional model
for pancreatic ductal adenocarcinoma organoids. Nat Mater.
21:110–119. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kim S, Min S, Choi YS, Jo SH, Jung JH, Han
K, Kim J, An S, Ji YW, Kim YG and Cho SW: Tissue extracellular
matrix hydrogels as alternatives to Matrigel for culturing
gastrointestinal organoids. Nat Commun. 13:16922022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Komor AC, Badran AH and Liu DR:
CRISPR-Based technologies for the manipulation of eukaryotic
genomes. Cell. 169:5592017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Aguirre AJ, Meyers RM, Weir BA, Vazquez F,
Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, et
al: Genomic copy number dictates a gene-independent cell response
to CRISPR/Cas9 targeting. Cancer Discov. 6:914–929. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sharma G, Sharma AR, Bhattacharya M, Lee
SS and Chakraborty C: CRISPR-Cas9: A preclinical and clinical
perspective for the treatment of human diseases. Mol Ther.
29:571–586. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Artegiani B, van Voorthuijsen L, Lindeboom
RGH, Seinstra D, Heo I, Tapia P, López-Iglesias C, Postrach D,
Dayton T, Oka R, et al: Probing the tumor suppressor function of
BAP1 in CRISPR-engineered human liver organoids. Cell Stem Cell.
24:927–943.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Matano M, Date S, Shimokawa M, Takano A,
Fujii M, Ohta Y, Watanabe T, Kanai T and Sato T: Modeling
colorectal cancer using CRISPR-Cas9-mediated engineering of human
intestinal organoids. Nat Med. 21:256–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Erlangga Z, Wolff K, Poth T, Peltzer A,
Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP, et
al: Potent antitumor activity of liposomal irinotecan in an
organoid- and CRISPR-Cas9-based murine model of gallbladder cancer.
Cancers (Basel). 11:19042019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Dekkers JF, Whittle JR, Vaillant F, Chen
HR, Dawson C, Liu K, Geurts MH, Herold MJ, Clevers H, Lindeman GJ
and Visvader JE: Modeling breast cancer using CRISPR-Cas9-mediated
engineering of human breast organoids. J Natl Cancer Inst.
112:540–544. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhan T, Rindtorff N, Betge J, Ebert MP and
Boutros M: CRISPR/Cas9 for cancer research and therapy. Semin
Cancer Biol. 55:106–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Vaishnavi A, Juan J, Jacob M, Stehn C,
Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett
CS, et al: Transposon mutagenesis reveals RBMS3 silencing as a
promoter of malignant progression of BRAFV600E-driven lung
tumorigenesis. Cancer Res. 82:4261–4273. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Takeda H, Kataoka S, Nakayama M, Ali MAE,
Oshima H, Yamamoto D, Park JW, Takegami Y, An T, Jenkins NA, et al:
CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids
provides functional validation for colorectal cancer driver genes.
Proc Natl Acad Sci USA. 116:15635–15644. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Artegiani B, Hendriks D, Beumer J, Kok R,
Zheng X, Joore I, de Sousa Lopes SC, van Zon J, Tans S and Clevers
H: Fast and efficient generation of knock-in human organoids using
homology-independent CRISPR-Cas9 precision genome editing. Nat Cell
Biol. 22:321–331. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hendriks D, Artegiani B, Hu H, de Sousa
Lopes SC and Clevers H: Establishment of human fetal hepatocyte
organoids and CRISPR-Cas9-based gene knockin and knockout in
organoid cultures from human liver. Nat Protoc. 16:182–217. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lo YH, Kolahi KS, Du Y, Chang CY,
Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA,
et al: A CRISPR/Cas9-engineered ARID1A-deficient human gastric
cancer organoid model reveals essential and nonessential modes of
oncogenic transformation. Cancer Discov. 11:1562–1581. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yao Q, Cheng S, Pan Q, Yu J, Cao G, Li L
and Cao H: Organoids: Development and applications in disease
models, drug discovery, precision medicine, and regenerative
medicine. MedComm (2020). 5:e7352024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Silvestri VL, Henriet E, Linville RM, Wong
AD, Searson PC and Ewald AJ: A tissue-engineered 3D microvessel
model reveals the dynamics of mosaic vessel formation in breast
cancer. Cancer Res. 80:4288–4301. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu X, Taftaf R, Kawaguchi M, Chang YF,
Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel DB, et
al: Homophilic CD44 interactions mediate tumor cell aggregation and
polyclonal metastasis in patient-derived breast cancer models.
Cancer Discov. 9:96–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cheung KJ, Gabrielson E, Werb Z and Ewald
AJ: Collective invasion in breast cancer requires a conserved basal
epithelial program. Cell. 155:1639–1651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Boos SL, Loevenich LP, Vosberg S,
Engleitner T, Öllinger R, Kumbrink J, Rokavec M, Michl M, Greif PA,
Jung A, et al: Disease modeling on tumor organoids implicates AURKA
as a therapeutic target in liver metastatic colorectal cancer. Cell
Mol Gastroenterol Hepatol. 13:517–540. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sánchez-Botet A, Quandt E, Masip N,
Escribá R, Novellasdemunt L, Gasa L, Li VSW, Raya Á, Clotet J and
Ribeiro MPC: Atypical cyclin P regulates cancer cell stemness
through activation of the WNT pathway. Cell Oncol (Dordr).
44:1273–1286. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Harada K, Sakamoto N, Ukai S, Yamamoto Y,
Pham QT, Taniyama D, Honma R, Maruyama R, Takashima T, Ota H, et
al: Establishment of oxaliplatin-resistant gastric cancer
organoids: Importance of myoferlin in the acquisition of
oxaliplatin resistance. Gastric Cancer. 24:1264–1277. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai
S, Pan H, Asad M, Martin ML, Sigouros M, Rowdo FM, et al:
Extracellular matrix in synthetic hydrogel-based prostate cancer
organoids regulate therapeutic Response to EZH2 and DRD2
Inhibitors. Adv Mater. 34:e21000962022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L,
Xia F, Fu G, Deng Y, Pan M, et al: Patient-Derived organoids
predict chemoradiation responses of locally advanced rectal cancer.
Cell Stem Cell. 26:17–26.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Vlachogiannis G, Hedayat S, Vatsiou A,
Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford
I, Burke R, et al: Patient-derived organoids model treatment
response of metastatic gastrointestinal cancers. Science.
359:920–926. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ganesh K, Wu C, O'Rourke KP, Szeglin BC,
Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, et al:
A rectal cancer organoid platform to study individual responses to
chemoradiation. Nat Med. 25:1607–1614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tiriac H, Belleau P, Engle DD, Plenker D,
Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche
RE, Jang GH, et al: Organoid profiling identifies common responders
to chemotherapy in pancreatic cancer. Cancer Discov. 8:1112–1129.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ji S, Feng L, Fu Z, Wu G, Wu Y, Lin Y, Lu
D, Song Y, Cui P, Yang Z, et al: Pharmaco-proteogenomic
characterization of liver cancer organoids for precision oncology.
Sci Transl Med. 15:eadg33582023. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Jensen LH, Rogatto SR, Lindebjerg J,
Havelund B, Abildgaard C, do Canto LM, Vagn-Hansen C, Dam C,
Rafaelsen S and Hansen TF: Precision medicine applied to metastatic
colorectal cancer using tumor-derived organoids and in-vitro
sensitivity testing: A phase 2, single-center, open-label, and
non-comparative study. J Exp Clin Cancer Res. 42:1152023.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Minoli M, Cantore T, Hanhart D, Kiener M,
Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V,
Rodriguez-Calero A, et al: Bladder cancer organoids as a functional
system to model different disease stages and therapy response. Nat
Commun. 14:22142023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Neal JT, Li X, Zhu J, Giangarra V,
Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et
al: Organoid Modeling of the Tumor Immune Microenvironment. Cell.
175:1972–1988.e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Bozkus CC and Bhardwaj N: Tumor
organoid-originated biomarkers predict immune response to PD-1
blockade. Cancer Cell. 39:1187–1189. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Cattaneo CM, Dijkstra KK, Fanchi LF,
Kelderman S, Kaing S, van Rooij N, van den Brink S, Schumacher TN
and Voest EE: Tumor organoid-T-cell coculture systems. Nat Protoc.
15:15–39. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Meng Q, Xie S, Gray GK, Dezfulian MH, Li
W, Huang L, Akshinthala D, Ferrer E, Conahan C, Perea Del Pino S,
et al: Empirical identification and validation of tumor-targeting T
cell receptors from circulation using autologous pancreatic tumor
organoids. J Immunother Cancer. 9:e0032132021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dijkstra KK, Cattaneo CM, Weeber F,
Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL,
Kaing S, Kelderman S, et al: Generation of tumor-reactive T cells
by co-culture of peripheral blood lymphocytes and tumor organoids.
Cell. 174:1586–1598.e12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Votanopoulos KI, Forsythe S, Sivakumar H,
Mazzocchi A, Aleman J, Miller L, Levine E, Triozzi P and Skardal A:
Model of patient-specific immune-enhanced organoids for
immunotherapy screening: Feasibility study. Ann Surg Oncol.
27:1956–1967. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kryeziu K, Moosavi SH, Bergsland CH, Guren
MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen
A and Lothe RA: Increased sensitivity to SMAC mimetic LCL161
identified by longitudinal ex vivo pharmacogenomics of recurrent,
KRAS mutated rectal cancer liver metastases. J Transl Med.
19:3842021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Choi YJ, Lee H, Kim DS, Kim DH, Kang MH,
Cho YH, Choi CM, Yoo J, Lee KO, Choi EK, et al: Discovery of a
novel CDK7 inhibitor YPN-005 in small cell lung cancer. Eur J
Pharmacol. 907:1742982021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhou Z, Van der Jeught K, Fang Y, Yu T, Li
Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, et al: An organoid-based
screen for epigenetic inhibitors that stimulate antigen
presentation and potentiate T-cell-mediated cytotoxicity. Nat
Biomed Eng. 5:1320–1335. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Cho K, Ro SW, Lee HW, Moon H, Han S, Kim
HR, Ahn SH, Park JY and Kim DY: YAP/TAZ suppress drug penetration
into hepatocellular carcinoma through stromal activation.
Hepatology. 74:2605–2621. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Grebenyuk S and Ranga A: Engineering
organoid vascularization. Front Bioeng Biotechnol. 7:392019.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Strobel HA, Moss SM and Hoying JB:
Vascularized tissue organoids. Bioengineering (Basel). 10:1242023.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bhat SM, Badiger VA, Vasishta S,
Chakraborty J, Prasad S, Ghosh S and Joshi MB: 3D tumor
angiogenesis models: Recent advances and challenges. J Cancer Res
Clin Oncol. 147:3477–3494. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wörsdörfer P, Dalda N, Kern A, Krüger S,
Wagner N, Kwok CK, Henke E and Ergün S: Generation of complex human
organoid models including vascular networks by incorporation of
mesodermal progenitor cells. Sci Rep. 9:156632019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Shirure VS, Bi Y, Curtis MB, Lezia A,
Goedegebuure MM, Goedegebuure SP, Aft R, Fields RC and George SC:
Tumor-on-a-chip platform to investigate progression and drug
sensitivity in cell lines and patient-derived organoids. Lab Chip.
18:3687–3702. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Mazio C, Casale C, Imparato G, Urciuolo F
and Netti PA: Recapitulating spatiotemporal tumor heterogeneity in
vitro through engineered breast cancer microtissues. Acta Biomater.
73:236–249. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Nashimoto Y, Hayashi T, Kunita I, Nakamasu
A, Torisawa YS, Nakayama M, Takigawa-Imamura H, Kotera H, Nishiyama
K, Miura T and Yokokawa R: Integrating perfusable vascular networks
with a three-dimensional tissue in a microfluidic device. Integr
Biol (Camb). 9:506–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Grönholm M, Feodoroff M, Antignani G,
Martins B, Hamdan F and Cerullo V: Patient-Derived organoids for
precision cancer immunotherapy. Cancer Res. 81:3149–3155. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Meng Q, Liu Z, Rangelova E, Poiret T,
Ambati A, Rane L, Xie S, Verbeke C, Dodoo E, Del Chiaro M, et al:
Expansion of tumor-reactive T cells from patients with pancreatic
cancer. J Immunother. 39:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Almeqdadi M, Mana MD, Roper J and Yilmaz
ÖH: Gut organoids: Mini-tissues in culture to study intestinal
physiology and disease. Am J Physiol Cell Physiol. 317:C405–C419.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Vazquez-Armendariz AI and Tata PR: Recent
advances in lung organoid development and applications in disease
modeling. J Clin Invest. 133:e1705002023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Shi R, Radulovich N, Ng C, Liu N, Notsuda
H, Cabanero M, Martins-Filho SN, Raghavan V, Li Q, Mer AS, et al:
Organoid cultures as preclinical models of non-small cell lung
cancer. Clin Cancer Res. 26:1162–1174. 2020. View Article : Google Scholar : PubMed/NCBI
|
